| Literature DB >> 31843577 |
Zohreh Jahanafrooz1, Behzad Baradaran1, Jafar Mosafer2, Mahmoud Hashemzaei3, Tayebeh Rezaei4, Ahad Mokhtarzadeh5, Michael R Hamblin6.
Abstract
Nucleic acid vaccines (NAVs) have recently been tested as a cancer therapy. DNA and mRNA vaccines deliver genetic information encoding tumor antigens (TAs) to the host, which then produces immune responses against cancer cells that express the TAs. Although NAVs are easy, safe, and simple to manufacture, they have not so far been considered viable alternatives to peptide vaccines. Choosing the right TAs, insufficient immunogenicity, and the immunosuppressive nature of cancer are some challenges to this approach. In this review, we discuss approaches that been used to improve the efficiency of anticancer NAVs.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31843577 PMCID： PMC7080609 DOI： 10.1016/j.drudis.2019.12.003
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851